Triglyceride-Glucose Index Independently Linked to All-Cause Mortality
By Elana Gotkine HealthDay Reporter
FRIDAY, June 21, 2024 -- The triglyceride-glucose (TyG) index is independently associated with all-cause mortality among patients with heart failure and chronic kidney disease (CKD), according to a study published online June 12 in ESC Heart Failure.
Yang Chen, from the Sun Yat-sen University in Guangzhou, China, and colleagues examined the association of the TyG index with overall mortality in individuals concurrently experiencing heart failure and CKD. Individuals underwent quartile stratification based on the TyG index using the Medical Information Mart for Intensive Care IV (Version 2.2) repository. Data were included for a cohort of 1,537 heart failure and CKD patients.
The researchers found that elevated TyG levels were an independent risk factor for both in-hospital and one-year mortality. A rising, nonlinear association was seen between TyG levels and all-cause mortality. A statistically significant reduction in survival rates was demonstrated by Kaplan-Meier survival curves in the high versus low TyG index group.
"Empirical evidence suggests the TyG index as a powerful stratification tool for risk assessment and therapeutic management in these patients," the authors write. "Subsequent research is crucial to ascertain if optimized regulation of the TyG index can enhance prospective clinical outcomes."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-06-22 03:15
Read more
- Comorbid Diabetes Increases Risk for Lower Extremity Amputation With Kidney Disease
- AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
- Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
- Grandparents & Grandkids: Poll Shows Them Helping Each Other
- Adult Hypertension Prevalence 47.7 Percent From August 2021 to August 2023
- Halloween Can Be Extra Scary for Folks With Dementia. An Expert Offers Caregiver Tips
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions